Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
14.00
-0.79 (-5.31%)
Mar 31, 2025, 10:01 AM EDT - Market open
Denali Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,001,832
Market Cap
2.03B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
DNLI News
- 4 days ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 10 days ago - Denali Therapeutics: Vast Pipeline, First Approval Up Ahead - Seeking Alpha
- 4 weeks ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 7 weeks ago - Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - GlobeNewsWire
- 2 months ago - Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
- 2 months ago - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains - Seeking Alpha
- 2 months ago - Denali Therapeutics ALS drug fails in mid-stage trial - Reuters
- 2 months ago - Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - GlobeNewsWire